Recro Pharma (REPH) Stock Rating Lowered by ValuEngine

Share on StockTwits

ValuEngine downgraded shares of Recro Pharma (NASDAQ:REPH) from a buy rating to a hold rating in a research report sent to investors on Friday morning.

A number of other equities research analysts have also issued reports on REPH. Oppenheimer set a $18.00 price objective on shares of Recro Pharma and gave the company a buy rating in a report on Wednesday, August 8th. Janney Montgomery Scott set a $13.00 target price on shares of Recro Pharma and gave the company a buy rating in a report on Monday, October 1st. Piper Jaffray Companies set a $10.00 price target on Recro Pharma and gave the stock a buy rating in a research report on Thursday, November 8th. Finally, Zacks Investment Research upgraded Recro Pharma from a hold rating to a strong-buy rating and set a $8.25 target price for the company in a research report on Wednesday, November 7th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $12.88.

NASDAQ:REPH opened at $6.57 on Friday. Recro Pharma has a 1-year low of $4.78 and a 1-year high of $13.05. The stock has a market capitalization of $140.68 million, a PE ratio of -3.31 and a beta of -0.51. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 4.04.

Recro Pharma (NASDAQ:REPH) last posted its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.03. Recro Pharma had a negative net margin of 79.42% and a negative return on equity of 220.42%. The business had revenue of $18.28 million for the quarter, compared to analysts’ expectations of $16.77 million. On average, analysts forecast that Recro Pharma will post -2.67 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Cadence Capital Management LLC grew its holdings in Recro Pharma by 6.6% in the 2nd quarter. Cadence Capital Management LLC now owns 151,323 shares of the specialty pharmaceutical company’s stock valued at $760,000 after buying an additional 9,381 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Recro Pharma by 5.2% during the 2nd quarter. Renaissance Technologies LLC now owns 381,300 shares of the specialty pharmaceutical company’s stock worth $1,914,000 after acquiring an additional 18,700 shares in the last quarter. Virtu Financial LLC acquired a new position in Recro Pharma during the 3rd quarter worth about $156,000. Wells Fargo & Company MN raised its position in Recro Pharma by 45.4% in the 1st quarter. Wells Fargo & Company MN now owns 76,832 shares of the specialty pharmaceutical company’s stock valued at $846,000 after purchasing an additional 23,984 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in Recro Pharma in the 2nd quarter valued at about $154,000. Hedge funds and other institutional investors own 52.81% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Story: How Short Selling Works

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply